Gerald Clarke | 08/12/2013
When GE Healthcare recently withdrew their Fetal Bovine Serum (FBS) products due to non-conformancies, it highlighted the real need for product safety and traceability practices in the field. Pharma IQ spoke to Rosemary Versteegen, CEO of the International Serum Industry Association about this case and what the industry can learn from it.
To continue reading this story Click Here
RECOMMENDED
The Trust Equation: Why Transparency Defines the Future Winners in Contract Manufacturing
2025-12-17
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More